Castagna | Jotup

MannKind Announces CFO Transition

Retrieved on:

화요일, 3월 26, 2024

Castagna, Professional corporation, KPMG, Information technology, CFO, Business, MannKind Corporation, Patient, Accounting, Adamas, MBA, Investment, KPMG LLP, Retirement, Loyola Marymount University, Deleveraging, CPA, Management

Mr. Binder plans to remain at MannKind through the end of the year as Executive Vice President, Special Projects.

Key Points:

Mr. Binder plans to remain at MannKind through the end of the year as Executive Vice President, Special Projects.
“We are excited to have Chris join us at such a pivotal time as our new CFO,” said Michael Castagna, PharmD., Chief Executive Officer for MannKind Corporation.
We are pleased that Steve will remain with MannKind for the rest of 2024, allowing for an optimal transition with Chris.”
“I look forward to working with Chris and remain totally committed to MannKind’s continued success,” said Steve Binder, Chief Financial Officer.
His earlier career also included senior financial roles at InterMune, Inc., Dynavax Technologies Corporation and MannKind.

UVU School of Aviation Sciences Becomes First in Nation to Fully Use Unleaded Fuel

Retrieved on:

화요일, 4월 18, 2023

Provo, Utah, April 18, 2023 (GLOBE NEWSWIRE) -- The School of Aviation Sciences at Utah Valley University (UVU) will be the first collegiate flight training program in the nation to switch to fully unleaded aviation fuel (UL94) for its training fleet.

Key Points:

Provo, Utah, April 18, 2023 (GLOBE NEWSWIRE) -- The School of Aviation Sciences at Utah Valley University (UVU) will be the first collegiate flight training program in the nation to switch to fully unleaded aviation fuel (UL94) for its training fleet.
Partnering with Swift Fuels, a fuel research and development company based in Indiana, the first shipment of unleaded aviation fuel known as UL94 arrived at UVU’s fuel farm on April 13.
Unleaded fuel, while used in cars for the past 50 years, is not the standard in piston-engine aircraft.
Nick Marsh, supervisor of aviation operations at UVU, said he is looking forward to the change to unleaded fuel.

OptimizeRx’s Karina Castagna Named to MM+M’s 40 Under 40 List of the Medical Marketing Industry’s Brightest Young Stars

Retrieved on:

목요일, 2월 9, 2023

Health, Education, Physician, Castagna, Patient, Cystic fibrosis, Prescription, Growth, Cystic Fibrosis Foundation, Pharmaceutical industry

(the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, today announced its senior vice president of access and adherence, Karina Castagna, has been named to MM+M’s 40 Under 40 List for her accomplishments and contributions to the healthcare marketing industry.

Key Points:

(the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, today announced its senior vice president of access and adherence, Karina Castagna, has been named to MM+M’s 40 Under 40 List for her accomplishments and contributions to the healthcare marketing industry.
In its fourth year, the 40 Under 40 list shines a light on the young marketers whose leadership, strategic thinking and digital facility have contributed to the industry’s continued growth.
The list includes individuals from a range of employers, from pharma and biotech companies and agencies to device manufacturers, analytics firms and health media.
Castagna joined OptimizeRx in 2021 to expand her impact on physician and provider access to innovative digital solutions.

UPDATE – Surveyed Physicians Say Access Challenges Impact Their Care Plans for up to 33% of Patients

Retrieved on:

수요일, 4월 20, 2022

(the Company)(Nasdaq: OPRX),a leading provider of point-of-care technology solutions helping patients start and stay on therapy, today announced the results of a survey of 102 specialist physicians highlighting how inefficient access pathways negatively impact patient care.

Key Points:

(the Company)(Nasdaq: OPRX),a leading provider of point-of-care technology solutions helping patients start and stay on therapy, today announced the results of a survey of 102 specialist physicians highlighting how inefficient access pathways negatively impact patient care.
Specifically, the survey found on average that physicians would make a different therapy choice for 33% of patients if medication access was not a factor, and physicians had to change their treatment plan for 26% of patients due to medication access challenges.
EHR-based solutions present new opportunities for market access teams to streamline prescribing and therapy initiation processes, reducing the impact market access challenges have on treatment choice.
Physicians continue to struggle with the time taken, cost incurred, and resources expended to start patients on medications particularly forspecialty brands.

1 in 3 Surveyed Physicians Say They Would Make a Different Treatment Choice If Medication Access Was Not a Factor

Retrieved on:

화요일, 4월 19, 2022

Specifically, the survey found that physicians would make a different therapy choice for one out of three patients if medication access was not a factor, and physicians had to change their treatment plan in one out of four patients due to medication access challenges.

Key Points:

Specifically, the survey found that physicians would make a different therapy choice for one out of three patients if medication access was not a factor, and physicians had to change their treatment plan in one out of four patients due to medication access challenges.
EHR-based solutions present new opportunities for market access teams to streamline prescribing and therapy initiation processes, reducing the impact market access challenges have on treatment choice.
69% of physicians ranked the process of starting patients on a specialty medication as very or extremely difficult.
Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.

MannKind Corporation to Present at the 2019 Cantor Global Healthcare Conference

Retrieved on:

목요일, 9월 26, 2019

Hypertension, MannKind Corporation, Thousand Oaks, California, RTT, Intercontinental, Pulmonary hypertension, Castagna, NASDAQ, Economy of the United States, Companies, New York City

WESTLAKE VILLAGE, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced today that it will be featured as a presenting company at the 2019 Cantor Global Healthcare Conference on Thursday, October 3, 2019 at 9:30 am (ET) at the InterContinental New York Barclay Hotel in New York City.

Key Points:

WESTLAKE VILLAGE, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced today that it will be featured as a presenting company at the 2019 Cantor Global Healthcare Conference on Thursday, October 3, 2019 at 9:30 am (ET) at the InterContinental New York Barclay Hotel in New York City.
Presenting from the Company will be its Chief Executive Officer, Michael Castagna.
Interested parties can access a link to the live webcast of the presentation from the News & Events section of the Company's website at http://www.mannkindcorp.com .
The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com .